Skip to main content
SpringerLink
Log in

Use of beta-adrenoceptor blockers in patients with congestive heart failure

  • Beta-Blockers
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

The beneficial effect of chronic beta-blockade in patients with congestive heart failure has been repeatedly shown since its introduction into treatment for this condition in 1975. Still this kind of therapy remains controversial, it is sometimes regarded as a therapeutic paradox, and its use is mainly limited to specialist centers. Various favorable effects of beta-blockers in patients with heart failure due to idiopathic dilated cardiomyopathy and ischemic heart disease have been demonstrated, the principal among them being reduction in energy requirements and ischemia, antiarrhythmogenic effect, improvement of diastolic function, protection of myocytes against catecholamine overload, centrally mediated increase in vagal tone, upregulation of betaadrenergic receptors, and possible blockade of autoantibodies against beta1-receptors. Although most of the studies used metoprolol, these effects may be relevant to certain other beta-blockers. Despite very solid pathophysiological and pharmacological rationales for the use of beta-blockade, a major obstacle for a general acceptance of this therapeutic concept is the striking contrast between hemodynamic changes during the acute effect and long-term treatment. When titrated carefully from very low doses and used with a true commitment to long-term treatment, beta-blockers have been shown to prevent further deterioration of heart failure and to improve hemodynamics, exercise tolerance, quality of life, and prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Åblad B, Abrahamson T, Björkman J-A, Bjurö T, Ek L, Sjöquist P-O; Effects of metoprolol on ischemic myocardial regional function and oxygen supply/demand ratio in the dog. In: Hugenholts PG, Goldman BS, eds.Unstable Angina, Current Concepts and Management. New York: Schattauer, 1985:159–170.

    Google Scholar 

  • Åblad B, Björkman J-A, Edvardsson N, Hansson G. A beta-adrenergic mechanism in the arterial wall possibly involved in genesis of cardiovascular disease.Fed Proc 1987;46:974.

    Google Scholar 

  • Åblad B, Björkman J-A, Gustafsson D, Hansson G, Östlund-Lindqvist A-M, Pettersson K. The role of sympathetic activity in atherogenesis—effects of beta-blockade.Am Heart J 1988;116:322–327.

    Google Scholar 

  • Åblad B, Bjurö T, Björkman J-A, Edström T, Olsson G. Role of central nervous beta-adrenoceptors in the prevention of ventricular fibrillation through augmentation of cardiac vagal tone.J Am Coll Cardiol 1991;17:165.

    Google Scholar 

  • Anderson JL, Rodier HE, Green LS. Comparative effects of beta-adrenergic blocking drugs in experimental ventricular fibrillation threshold.Am J Cardiol 1983;51:1196–1202.

    Google Scholar 

  • Anderson JL, Lutz JR, Gilbert EM, et al. A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy.Am J Cardiol 1985;55:471–475.

    Google Scholar 

  • Andersson B, Blomström-Lundqvist C, Hedner T, Waagstein F. Exercise hemodynamics and myocardial metabolism during long-term beta-adrenergic blockade in severe heart failure.J Am Coll Cardiol 1991;18:1059–1066.

    Google Scholar 

  • Andersson B, Lomsky L, Waagstein F. The link between acute haemodynamic adrenergic beta-blockade and long-term effects in patients with heart failure. A study on diastolic function, heart rate and myocardial metabolism following intravenous metoprolol.Eur Heart J 1993;14:1375–1385.

    Google Scholar 

  • Asseman P, McFadden E, Bauchart JJ, Loubeyre C, Thery C. Why do beta-blockers help in idiopathic dilated cardiomyopathy-frequency mismatch?Lancet 1994;344:803–804.

    Google Scholar 

  • Barnett DB. Beta-blockers in heart failure: A therapeutic paradox.Lancet 1994;343:557–558.

    Google Scholar 

  • Bennett SK, Fisher ML, Krichten C, Patten RD, Greenberg NL, Gottlieb SS. Heart failure with known coronary artery disease: Comparison of changes in ejection fraction with betablocker and placebo (abstr).J Am Coll Cardiol 1993;21(Suppl A):114.

    Google Scholar 

  • Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results.JAMA 1982;247:1707–1714.

    Google Scholar 

  • Brezis M, Stalnikowicz R, Hasin J. Beta-blockade in congestive cardiomyopathy.Am Heart J 1981;101:357–357.

    Google Scholar 

  • Bristow MR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents.Am J Cardiol 1993;71:12C-22C.

    Google Scholar 

  • Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.N Engl J Med 1982;307:205–211.

    Google Scholar 

  • Bristow MR, Anderson FL, Port D, et al. Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy.Circulation 1991;84;1024–1039.

    Google Scholar 

  • Bristow MR, O'Connell JB, Gilbert EM, et al. Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy.Circulation 1994;89:1632–1642.

    Google Scholar 

  • Brodde O. The functional importance of beta1 and beta2 adrenoceptors in the human heart.Am J Cardiol 1988;62:9C-24C.

    Google Scholar 

  • Brodde OE, Zerkovski H-R, Doetsch N, Motomura S, Khamssi M, Michel MC. Myocardial beta-adrenoceptor changes in heart failure: Concomitant reduction in beta1- and beta2-adrenoceptor function related to the degree of heart failure in patients with mitral valve disease.J Am Coll Cardiol 1989;14:323–331.

    Google Scholar 

  • Brodde OE, Daul A, Michel MC, Zerkowski HR. Importance of beta 2-adrenergic receptors in heart failure (Ger).Zeitschrift Kardiologie 1992;81(Suppl 4):71–78.

    Google Scholar 

  • Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure.Circulation 1986;73:503–510.

    Google Scholar 

  • Chatterjee K. Effects of captopril and a combination of hydralazine and isosorbide dinitrate on myocardial sympathetic tone in patients with severe congestive heart failure.Br Heart J 1986;56:152–157.

    Google Scholar 

  • Chidsey CA, Harrison DC, Braunwald E. Augmentation of the plasma noradrenaline response to exercise in patients with congestive heart failure.N Engl J Med 1962;267:650–654.

    Google Scholar 

  • Cohn JN, Levine TB, Olivari MJ, et al. Plasma noradrenaline as a guide to prognosis in patients with chronic congestive heart failure.N Engl J Med 1984;311:819–823.

    Google Scholar 

  • Cruickshank JM. The xamoterol experience in the treatment of heart failure.Am J Cardiol 1993;71:61C-64C.

    Google Scholar 

  • Currie PJ, Kelly MJ, McKenzie A, et al. Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy.J Am Coll Card 1984;3:203–209.

    Google Scholar 

  • Dargie HJ, McMurray JJV. Diagnosis and management of heart failure.Br Med J 1994;308:321–328.

    Google Scholar 

  • Das Gupta P, Broadhurst PA, Lahiri A. Improvement in congestive heart failure following chronic therapy with a new vasodilating beta-blocker: Carvedilol.Circulation 1989;80(Suppl II):II117.

    Google Scholar 

  • Das Gupta P, Broadhurst P, Raftery EB, Lahiri A. Value of carvedilol in congestive heart failure secondary to coronary artery disease.Am J Cardiol 1990;66:1118–1123.

    Google Scholar 

  • Das Gupta P, Lahiri A. Can intravenous beta blockade predict long-term haemodynamic benefit in chronic congestive heart failure secondary to ischemic heart disease? A comparison between intravenous and oral carvedilol.Clin Invest 1992a;70(Suppl 1):S98-S104.

    Google Scholar 

  • Das Gupta P, Lahiri A. Can intravenous beta blockade predict long-term benefit in chronic congestive heart failure secondary to ischemic heart disease? A comparison of intravenous with oral carvedilol.J Cardiovasc Pharmacol 1992b;19(Suppl 1):S62-S67.

    Google Scholar 

  • De la Bastie D, Levitsky D, Rappaport L, et al. Function of the sarcoplasmic reticulum and expression of its Ca2+-ATPase gene in pressure overload-induced cardiac hypertrophy in the rat.Circ Res 1990;66:554–564.

    Google Scholar 

  • Doughty RN, MacMahon S, Sharpe N. Beta-blockers in heart failure: Promising or proved?J Am Coll Cardiol 1994;23:814–821.

    Google Scholar 

  • Eckberg DL. Beta-adrenergic blockade may prolong life in post-infarction patients in part by increasing vagal cardiac inhibition.Med Hypotheses 1984;15:421–432.

    Google Scholar 

  • Eichorn EJ. The paradox of β-adrenergic blockade for the management of congestive heart failure.Am J Med 1992;92:527–538.

    Google Scholar 

  • Eichhorn EJ. The paradox of β-adrenergic blockers for the management of congestive heart failure. In: Barnett DB, Pouleur H, Francis GS, eds.Congestive Cardiac Failure. Pathophysiology and Treatment. New York: Marcel Dekker, 1993:213–250.

    Google Scholar 

  • Eichhorn EJ, Bedotto JB, Hatfield B, et al. Improvement in contractile performance in patients with congestive failure by chronic beta-blocker therapy with bucindolol.Circulation 1989;80(Suppl II):II117.

    Google Scholar 

  • Eichhorn EJ, Bedotto JB, Malloy CR, et al. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure: Improvements in hemodynamic, contractile, and diastolic performance with bucindolol.Circulation 1990;82:473–483.

    Google Scholar 

  • Eichhorn EJ, Sobotka P. Novel approaches to congestive heart failure: Use of beta-adrenergic blockade.Coronary Artery Disease 1994;5:101–106.

    Google Scholar 

  • Eiswirth CC, Bowden RE, Kazamias T, Fowler M, Bristow MR. Treatment of adriamycin cardiomyopathy with metoprolol.Circulation 1986;74(Suppl 2):310.

    Google Scholar 

  • Engelmeir RS, O'Connel JB, Walsh R, Rad N, Scanlon PF, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: A double-blind, randomized, placebo-controlled trial.Circulation 1985;72:536–546.

    Google Scholar 

  • FDC Reports, June 27, 1994, p. 8.

  • Fisher ML, Gottlieb SS, Plotnick GD, et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: A randomized trial.J Am Coll Cardiol 1994;23:943–950.

    Google Scholar 

  • Fowler MB. Controlled trials with beta blockers in heart failure: Metoprolol as the prototype.Am J Cardiol 1993;71:45C-53C.

    Google Scholar 

  • Fowler MB, Bristow MR, Laser JA, Ginsburg R, Scott LB, Schroeder JS. Beta blocker therapy in severe heart failure: Improvement related to beta1-adrenergic receptor up regulation?Circulation 1984;(Suppl II):II112.

  • Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR. Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: Progressive receptor down-regulation and subsensitivity to agonist response.Circulation 1986;74:1290–1302.

    Google Scholar 

  • Francis GS, Benedict C, Johnstone DE, et al. for the SOLVD Investigators. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: A substudy of the Studies Of Left Ventricular Dysfunction (SOLVD).Circulation 1990;82:1724–1729.

    Google Scholar 

  • Fu L-X, Bergh C-H, Hoebeke J, et al. Effect of metoprolol on activity of beta-adrenoceptor coupled to guanine nucleotide binding regulatory proteins in adriamycin-induced cardiotoxicity.Basic Res Cardiol 1991;86:117–126.

    Google Scholar 

  • Fukunami M, Hashimura K, Ohmori M, et al. Effectiveness of long-term beta-blocker therapy for dilated cardiomyopathy—echocardiographical follow-up.Cardiovasc Drugs Ther 1991;5:463–470.

    Google Scholar 

  • Garg R, Yusuf S. Current and ongoing randomized trials in heart failure and left ventricular dysfunction.J Am Coll Cardiol 1993;22(Suppl A):194A-197A.

    Google Scholar 

  • Gilbert EM, Mestroni L, Anderson JL, Woodly SL, Bristow MR. Can response to β-blocker therapy in idiopathic dilated cardiomyopathy be predicted by baseline parameters?Circulation 1989;80(Suppl II):II428.

    Google Scholar 

  • Gilbert EM, Anderson JL, Deitchman D, et al. Long-term beta-blocker—vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: A double-blind, randomized study of bucindolol versus placebo.Am J Med 1990;88:223–229.

    Google Scholar 

  • Gilbert EM, Olsen SL, Renlund DG, Bristow MR. Beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy.Am J Cardiol 1993;71:23C-29C.

    Google Scholar 

  • Gundersen T. Influence of heart size on mortality and reinfarction in patients treated with timolol after myocardial infarction.Br Heart J 1983;50:135–139.

    Google Scholar 

  • Gwathmey JK, Copelas L, MacKinnon R, et al. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure.Circ Res 1987;61:70–76.

    Google Scholar 

  • Heilbrunn SM, Shah P, Bristow MR, Valentine HA, Ginsburg R, Fowler MB. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy.Circulation 1989;79:483–490.

    Google Scholar 

  • Held P. Effects of beta-blockers on ventricular dysfunction after myocardial infarction: Tolerability and survival effects.Am J Cardiol 1993;71:39C-44C.

    Google Scholar 

  • Hjalmarson Å, Waagstein F. The role of beta-blockers in the treatment of cardiomyopathy and ischemic heart failure.Drugs 1994;47(Suppl 4):31–40.

    Google Scholar 

  • Hjalmarson Å, Herlitz J, Malek I, et al. Effects on mortality of metoprolol in acute myocardial infarction.Lancet 1981;2:823–827.

    Google Scholar 

  • Hoffbrand BI. Beta-adrenergic blockade in congestive cardiomyopathy.Lancet 1980;1:1031.

    Google Scholar 

  • Horn EM, Corwin SJ, Steinberg SF, et al. Reduced lymphocyte stimulatory guanine nucleotide regulatory protein and beta-adrenergic receptors in congestive heart failure and reversal with angiotensin converting enzyme inhibitor therapy.Circulation 1988;78:1373–1379.

    Google Scholar 

  • Ikram H, Fitzpatrick D. Double-blind trial of chronic oral beta-blockade in congestive cardiomyopathy.Lancet 1981;2:490–492.

    Google Scholar 

  • Ikram H, Chan W, Bennett SI, Bones PJ. Haemodynamic effects of acute beta-adrenergic receptor blockade in congestive cardiomyopathy.Br Heart J 1979;42:311–315.

    Google Scholar 

  • Ikram H, Fitzpatrick D, Crozier IG. Therapeutic controversies with use of beta-adrenoceptor blockade in heart failure.Am J Cardiol 1993;71:54C-60C.

    Google Scholar 

  • Insel PA, Ransnas LA. G proteins and cardiovascular disease.Circulation 1988;78:1503–1511.

    Google Scholar 

  • Jacob AS, Hafer JG. Selective (beta1) blockade in congestive cardiomyopathy.Am Heart J 1983;105:872–873.

    Google Scholar 

  • Jessup M. Beta-adrenergic blockade in congestive heart failure: Answering the old questions.J Am Coll Cardiol 1991;18:1067–1069.

    Google Scholar 

  • Kelly DT. Carvedilol in heart failure.Cardiology 1993;82(Suppl 3):45–49.

    Google Scholar 

  • Krukemyer JJ. Use of beta-adrenergic blocking agents in congestive heart failure.Clin Pharm 1990;9:853–863.

    Google Scholar 

  • Krum H, Schwartz B, Sackner-Bernstein J, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe heart failure treated with converting-enzyme inhibitors (abstr).J Am Coll Cardiol 1993;21:114.

    Google Scholar 

  • Kuhn H. Discussion (Workshop on Multicenter Research Project on Congestive Cardiomyopathy, London, 1978).Postgrad Med J 1978;54:475.

    Google Scholar 

  • Kukin ML, Kalman J, Gass A, Lotvin A, Buchholz C. Do beta blockers retain an acute negative inotropic effect despite chronic beta blockade in patients with heart failure?Circulation 1993;88:I104.

    Google Scholar 

  • Lechat P. β-Blockade treatment in heart failure: The Cardiac Insufficiency BIsoprolol Study (CIBIS) project.J Cardiovasc Pharm 1990;16(Suppl 5):S158-S163.

    Google Scholar 

  • Leung WH, Lau CP, Wong CK, Cheng CH, Tai YT, Lim SP. Improvement in exercise performance and hemodynamics by labetalol in patients with idiopathic dilated cardiomyopathy.Am Heart J 1990;199:884–890.

    Google Scholar 

  • Lindvall K, Olsson G, Rehnqvist N. Left ventricular function following withdrawal of chronic metoprolol treatment in patients with ischaemic heart disease. A double blind study.Eur Heart J 1986;7:1045–1052.

    Google Scholar 

  • Magnusson Y, Marullo S, Höyer S, et al. Mapping of a functional autoimmune epitope on the beta-1-adrenergic receptor in patients with idiopathic dilated cardiomyopathy.J Clin Invest 1990;86:1658–1663.

    Google Scholar 

  • Maisel AS. Treatment of heart failure with metoprolol: Beneficial immunologic effects.Circulation 1993;88(Suppl I):I105.

    Google Scholar 

  • Majid PA, Niznick J, Nishizaki S, Morris WM, Sole MJ. Acute hemodynamic and neurohumoral effects of pindolol: A betareceptor antagonist with high intrinsic sympathomimetic activity in patients with dilated cardiomyopathy.J Cardiovasc Pharmacol 1987;10:309–314.

    Google Scholar 

  • Massie BM, Leier CV, Unverferth DV. Hemodynamic changes following placebo administration: Implications for drug studies.Circulation 1984;70(Suppl II):II112.

    Google Scholar 

  • Matsumori A, Tominaga M, Kawai C. A questionnaire study of beta-adrenergic blockade in dilated cardiomyopathy in Japan.Jpn Circ J 1992;56:767–775.

    Google Scholar 

  • Mattioli AV, Parato VM, Vivoli D, Bergomi M. Heart insufficiency treated with beta-blocking agents. Comparison of responders and non-responders (in Italian).Cardiologia 1992;37:337–343.

    Google Scholar 

  • Metra M, D'Aloia A, Panina G, Nardi M, Giubbini R, Dei Cas L. Effects of acute and chronic carvedilol on resting and exercise hemodynamics of patients with idiopathic cardiomyopathy (abstr.)J Am Coll Cardiol 1993;21(Suppl A):114A.

    Google Scholar 

  • Murray DP, Murray RG, Littler WA. The effects of metoprolol given early in acute myocardial infarction on ventricular arrhythmias.Eur Heart J 1986;7:217–222.

    Google Scholar 

  • Nemanich JW, Veith RC, Abrass IB, Stratton JR. Effects of metoprolol on rest and exercise cardiac function and plasma catecholamines in chronic congestive heart failure secondary to ischemic or idiopathic cardiomyopathy.Am J Cardiol 1990;66:843–848.

    Google Scholar 

  • Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left ventricular function in idiopathic dilated cardiomyopathy.Circulation 1991;84(Suppl II):II564.

    Google Scholar 

  • Olsen SL, Yanowitz FG, Gilbert EM, et al. Beta-blocker related improvement in submaximal exercise tolerance in heart failure from idiopathic dilated cardiomyopathy (IDC).J Am Coll Cardiol 1992;19:146A.

    Google Scholar 

  • Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves symptoms and left ventricular function in patients with congestive heart failure due to ischemic or idiopathic dilated cardiomypathy (abstr).J Am Coll Cardiol 1993;21(Suppl A):114A.

    Google Scholar 

  • Olsson G, Rehnqvist N. Evaluation of anti-arrhythmic effect of metoprolol treatment after acute myocardial infarction.Am J Cardiol 1988;61:519–523.

    Google Scholar 

  • Olsson G, Rehnqvist N, Slögren A, Erhardt L, Lundman T. Long-term treatment with metoprolol after myocardial infarction: Effect on 3-year mortality and morbidity.J Am Coll Cardiol 1985;5:1428–1437.

    Google Scholar 

  • Olsson G, Oden A, Johansson L, Sjögren A, Rehnqvist N. Prognosis after withdrawal of chronic postinfarction metoprolol treatment: A 2–7 year follow-up.Eur Heart J 1988;9:365–372.

    Google Scholar 

  • Olsson G, Wikstrand J, Warnold I, et al. Metoprolol-induced reduction in postinfarction mortality: Pooled results from five double-blind randomized trials.Eur Heart J 1992;13;28–32.

    Google Scholar 

  • Östlund-Lindqvist A-M, Lindqvist P, Bräutigam J, Olsson G, Bondjers G, Nordborg C. The effect of metoprolol on diet-induced atherosclerosis in rabbits.Atherosclerosis 1988;8:40–45.

    Google Scholar 

  • Packer M. Pathophysiological mechanisms underlying the effects of β-adrenergic agonists and antagonists on functional capacity and survival in chronic heart failure.Circulation 1990;82(Suppl I):I77-I88.

    Google Scholar 

  • Paolisso G, Gambardella A, Marrazzo G, et al. Metabolic and cardiovascular benefits deriving from beta-adrenergic blockade in chronic congestive heart failure.Am Heart J 192;123:103–110.

  • Pedersen TR for the Norwegian Study Group. Six-year follow-up of the Norwegian Multicentre Study on timolol after acute myocardial infarction.N Engl J Med 1985;313:1055–1058.

    Google Scholar 

  • Persson H, Erhardt L. Beta receptor antagonists in the treatment of heart failure.Cardiovasc Drugs Ther 1991;5:589–604.

    Google Scholar 

  • Pollock SG, Lystash JC, Tedesco CL, Craddock GB, Smucker ML. Bucindolol-beta blockade with vasodilation improves congestive heart failure.Circulation 1989;80(Suppl II):II118.

    Google Scholar 

  • Pollock SG, Lystash J, Tedesco C, Craddock G, Smucker ML. Usefulness of bucindolol in congestive heart failure.Am J Cardiol 1990;66:603–607.

    Google Scholar 

  • Pouleur H, Hanet C, Rousseau MF. The efficacy and safety of chronic oral administration of xamoterol to patients with severe heart failure treated with ACE inhibitors.Br J Clin Pharmacol 1989;28:82S-83S.

    Google Scholar 

  • Rehnqvist N, Olsson G, Erhardt L, Ekman A-M. Metoprolol during acute myocardial infarction reduces ventricular arrhythmias both in the early stage and after the acute event.Int J Cardiol 1987;15:310–318.

    Google Scholar 

  • Rydén L, Ariniago R, Arnman K, et al. A double-blind trial of metoprolol in acute myocardial infarction. Effect on ventricular tachiarrhythmias.N Engl J Med 1983;308:614–618.

    Google Scholar 

  • Sano H, Kawabata N, Yonezawa K, Hirayama H, Sakuma I, Yasuda H. Metoprolol was more effective than captopril for dilated cardiomyopathy in Japanese patients.Circulation 1989;80(Suppl II):II118.

    Google Scholar 

  • Schramm MS, Marks ML, Olsen SL, Gilbert EM. Chronic beta-blocker therapy with carvedilol increases parasympathetic drive in heart failure.Circulation 1993;88(Suppl I):I104.

    Google Scholar 

  • Schulze K, Becker BF, Schultheiss HP. Antibodies to the ADP/ATP carrier, and autoantigen in myocarditis and dilated cardiomyopathy penetrate into myocardial cells and disturb energy metabolism in vivo.Circ Res 1989;64:179–192.

    Google Scholar 

  • Sigmund M, Reineke T. Beta receptor blockers in dilated cardiomyopathy (clinical aspects).Zeitschrift Kardiologie 1992;81(Suppl 4):65–70.

    Google Scholar 

  • Swedberg K. Initial experience with beta blockers in dilated cardiomyopathy.Am J Cardiol 1993;71:30C-38C.

    Google Scholar 

  • Swedberg K, Hjalmarson Å, Holmberg S. Effects of work and acute beta-receptor blockade on myocardial noradrenaline release in congestive cardiomyopathy.Clin Cardiol 1979a; 2:424–430.

    Google Scholar 

  • Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L for the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality.Circulation 1990;82:1730–1736.

    Google Scholar 

  • Swedberg K, Hjalmarson Å, Waagstein F, Wallentin I. Prolongation of survival in congestive cardiomyopathy during treatment with beta-receptor blockade.Lancet 1979b;i:1374–1376.

    Google Scholar 

  • Swedberg K, Hjalmarson Å, Waagstein F, Wallentin I. Beneficial effects of long-term beta-blockade in congestive cardiomyopathy.Br Heart J 1980a;44:117–133.

    Google Scholar 

  • Swedberg K, Hjalmarson Å, Waagstein F, Wallentin I. Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy.Br Heart J 1980b;44:134–142.

    Google Scholar 

  • The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction.N Engl J Med 1981;304:801–807.

    Google Scholar 

  • Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure.Am J Cardiol 1978;41:233–243.

    Google Scholar 

  • Tominaga M, Matsumori, Okada I, Yamada R, Chuichi K. Beta-blocker treatment of dilated cardiomyopathy. Beneficial effect of carteolol in mice.Circulation 1991;83:2021–2028.

    Google Scholar 

  • Van der Wall DD, Westera G, Visser FC, Eenige Van MJ, den Hollander W, Roos JP. Influence of metoprolol on myocardial uptake of free fatty acids in experimental myocardial ischemia.Curr Ther Res 1982;32:653–662.

    Google Scholar 

  • Vedin A, Wikstrand J, Wilhelmsson C, Wallentin I. Left ventricular function and beta-blockade in chronic ischemic heart disease.Br Heart J 1980;44:101–107.

    Google Scholar 

  • Waagstein F. Beta blockers in heart failure.Cardiology 1993a;82(Suppl 3):13–18.

    Google Scholar 

  • Waagstein F. Negative inotropic drugs in chronic congestive heart failure. In: Pharmacological Treatment of Heart Failure. Uppsala: Läkemedelsverket, 1993b:63–74.

    Google Scholar 

  • Waagstein F, Hjalmarson Å, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic blockade in congestive cardiomyopathy.Br Heart J 1975;37:1022–1036.

    Google Scholar 

  • Waagstein F, Hjalmarson Å, Swedberg K, Wallentin I. Beta-blockers in dilated cardiomyopathies: They work.Eur Heart J 1983;4(Suppl A):173–178.

    Google Scholar 

  • Waagstein F, Blomström-Lundquist C, Anderson B, Hjalmarson Å, Wallentin I. Long-term effects of metoprolol in severe heart failure due to ischemic cardiopathy, primary valve disease and diabetes.Circulation 1987;76(Suppl IV):IV358.

    Google Scholar 

  • Waagstein F, Caidahl K, Wallentin I, Bergh C-H, Hjalmarson Å. Long-term beta-blockade in congestive cardiomyopathy. Effects of acute and chronic metoprolol treatment followed by withdrawal and readministration of metoprolol.Circulation 1989;80:551–563.

    Google Scholar 

  • Waagstein F, Bristow MR, Swedberg K, et al. for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy.Lancet 1993a;342:1441–1446.

    Google Scholar 

  • Wallukat G, Morwinski M, Kowal K. Förster A, Boewer V, Wollenberger A. Autoantibodies against the beta-adrenergic receptor in human myocarditis and dilated cardiomyopathy: Beta-adrenergic agonism without desensitization.Eur Heart J 1991;12(Suppl D):178–181.

    Google Scholar 

  • White M, Gilbert M, Anderson JA, et al. Do beta-blocking agents improve left ventricular function in subjects with ischemic dilated cardiomyopathy? (abstr).J Am Coll Cardiol 1993;21:115.

    Google Scholar 

  • Wisenbaugh T, Katz I, Davis J, et al. Long-term (3 month) effects of a new β-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy.J Am Coll Cardiol 1993;21:1094–1100.

    Google Scholar 

  • Woodley SL, Gilbert EM, Anderson JL, et al. Differing effect of chronic beta-blockade with bucindolol on cardiac function in patients with idiopathic vs. ischemic cardiomyopathy.Circulation 1989;80(Suppl II):II118.

    Google Scholar 

  • Woodley SL, Gilbert EM, Anderson JL, et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy.Circulation 1991;84:2426–2441.

    Google Scholar 

  • Xamoterol: Revised indications.Lancet 1990;335:1394–1395.

    Google Scholar 

  • Yates JC, Beamish RE, Dhalla NS. Ventricular dysfunction and necrosis produced by adrenochrome metabolite of epinephrine. Relation to pathogenesis of catecholamine cardiomyopathy.Am Heart J 1981;102:210–221.

    Google Scholar 

  • Yokota Y, Nomura H, Kawai H, et al. Effects of long-term beta-blockade (metoprolol) therapy in patients with dilated cardiomyopathy.Jpn Circ J 1991;55:343–355.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Science, Astra Hässle AB, S-431 83, Mölndal, Sweden

    V. Panfilov MD, PhD, DSc, I. Wahlqvist & G. Olsson

Authors
  1. V. Panfilov MD, PhD, DSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Wahlqvist
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Olsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Panfilov, V., Wahlqvist, I. & Olsson, G. Use of beta-adrenoceptor blockers in patients with congestive heart failure. Cardiovasc Drug Ther 9, 273–287 (1995). https://doi.org/10.1007/BF00878672

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00878672

Key Words

Search

Navigation